Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases.
about
Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GNAnti-complement-factor H-associated glomerulopathies.Effect of complement Factor H on anti-FHbp serum bactericidal antibody responses of infant rhesus macaques boosted with a licensed meningococcal serogroup B vaccineAntibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome-Biomarkers of the Disease and Biopharmaceuticals.Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy.Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome.Diseases of complement dysregulation-an overview.Functional Characterization of the Disease-Associated N-Terminal Complement Factor H Mutation W198R.An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.Interpretation of Serological Complement Biomarkers in DiseaseBoth Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy
P2860
Q26741542-38109D3A-7A83-4ED0-8160-503E32D74623Q33434103-DEFAC0F8-083A-407B-9003-1A6E675D3A05Q36385023-F984CC6D-3D92-42B5-B7FB-636FABE9EFC9Q38718092-E9220AB3-9DB3-467B-921B-BCC545D47511Q42086661-DB4F2E41-1DC9-498B-B040-83456A119FD6Q42625961-157E0FCB-8575-456C-BA50-DC19B3D375D9Q48146844-16E993B8-7887-4B40-AF7F-E6812BFE5E7CQ48256943-94A4DAF4-D46E-4C26-B62E-D0C275AADDDDQ50100348-49098CB0-4F69-4166-98A6-20450D65137FQ51730313-0E4438F0-1C6D-41AE-A625-4EE0ED89DE65Q52316335-F59B6723-AAD3-4FED-918F-89495C5E0C48Q58566667-17A42F0C-87A5-4800-AC07-6F16B2DA6F28Q58586428-EB23C2D1-6757-46FC-A9B3-55E676BB2315
P2860
Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases.
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Anti-factor H autoantibodies i ...... ome: one target, two diseases.
@ast
Anti-factor H autoantibodies i ...... ome: one target, two diseases.
@en
type
label
Anti-factor H autoantibodies i ...... ome: one target, two diseases.
@ast
Anti-factor H autoantibodies i ...... ome: one target, two diseases.
@en
prefLabel
Anti-factor H autoantibodies i ...... ome: one target, two diseases.
@ast
Anti-factor H autoantibodies i ...... ome: one target, two diseases.
@en
P2093
P50
P356
P1476
Anti-factor H autoantibodies i ...... ome: one target, two diseases.
@en
P2093
Caroline Blanc
Matthias Buchler
Moglie Le Quintrec
Sophie Chauvet
T Sakari Jokiranta
Véronique Fremeaux-Bacchi
P304
P356
10.4049/JIMMUNOL.1402770
P407
P577
2015-04-27T00:00:00Z